Which of the following statements best describes the primary reason for the increased rate of mutation observed in cancer cells?

Core Concept

PILLAR 1 — MOLECULAR/CONCEPTUAL MECHANISM

Step-by-Step Analysis

DNA integrity depends on a multilayered surveillance network of repair enzymes that continuously scan the double helix for structural abnormalities. In healthy cells, base excision repair (BER) glycosylases such as OGG1 recognize and excise oxidized guanine residues (8-oxoguanine), while nucleotide excision repair (NER) complexes like XPA-XPF-ERCC1 detect bulky, helix-distorting adducts—including ultraviolet-induced cyclobutane pyrimidine dimers—and remove a short oligonucleotide segment surrounding the lesion. Mismatch repair (MMR), executed by the MutSα heterodimer (MSH2–MSH6) and MutLα (MLH1–PMS2), patrols newly synthesized DNA immediately behind the replication fork, binding to non-Watson-Crick base pairs and insertion-deletion loops that DNA polymerase δ or ε failed to correct via its intrinsic 3′→5′ exonuclease proofreading activity. Double-strand breaks, perhaps the most genotoxic lesions, are resolved through homologous recombination (requiring BRCA1, BRCA2, and RAD51) or non-homologous end joining (Ku70/Ku80, DNA-PKcs, XRCC4–Ligase IV). Tumor suppressor p53 orchestrates cell-cycle arrest at the G1/S checkpoint via transcriptional activation of p21, buying time for these repair pathways before S-phase entry. When any node in this network is lost—through somatic mutation, promoter hypermethylation, or chromosomal deletion—unrepaired lesions become fixed as permanent sequence variants during subsequent rounds of DNA replication. This phenomenon, termed the mutator phenotype, generates a self-reinforcing feedback loop: each additional mutation in a repair gene further relaxes genomic surveillance, accelerating the accumulation of subsequent mutations.

Why Other Options Are Wrong

PILLAR 2 — STEP-BY-STEP LOGIC

The question asks for the primary reason cancer cells exhibit an elevated mutation rate. One must distinguish between the rate at which DNA damage initially occurs and the rate at which that damage is converted into heritable sequence changes. Normal human cells experience tens of thousands of DNA lesions per day from endogenous reactive oxygen species, spontaneous hydrolytic deamination of cytosine to uracil, and environmental insults. Yet the observable mutation rate in healthy somatic tissue remains remarkably low—approximately 10⁻¹⁰ substitutions per base per division—precisely because the repair machinery described above catches nearly every anomaly. Cancer cells, by contrast, frequently harbor inactivating mutations or epigenetic silencing in MMR genes (e.g., MLH1 promoter methylation in microsatellite-unstable colorectal carcinoma), BER components, or homologous recombination genes (germline or somatic BRCA1/2 loss in breast and ovarian cancer). The DNA polymerase active site in a malignant cell does not inherently possess lower fidelity than in a normal cell; rather, the proofreading and post-replicative correction systems that would normally rescue polymerase errors are compromised. Therefore, the increased observed mutation rate in cancer cells arises because lesions that would be repaired in healthy tissue persist, are misread during the next S-phase, and become codified as point mutations, frameshifts, or chromosomal rearrangements. This logic directly validates option B: the diminution of DNA repair capacity is the proximate driver of mutational acceleration in malignancy.

PILLAR 3 — DISTRACTOR ANALYSIS

Option A — 'Increased error rate in DNA replication' — is the most seductive distractor because students conflate elevated mutation frequency with defective DNA synthesis. The critical distinction is that DNA polymerase catalytic fidelity, governed by geometric selection within the active site and the energetics of correct dNTP complementary base pairing, remains essentially unchanged in most cancer cells. The polymerase does not suddenly 'make more mistakes'; instead, the mistakes it inevitably makes go unrepaired. Selecting A reflects a misunderstanding of where the regulatory bottleneck lies: post-replicative quality control, not the synthetic reaction itself.

Option C — 'Increased rate of gene expression' — introduces a plausible biological change that does occur in many tumors (e.g., overexpression of MYC, upregulated ribosomal biogenesis) but has no direct mechanistic link to mutation accumulation. Transcriptional output does not alter the chemical stability of phosphodiester bonds or the thermodynamics of base pairing. Students who choose C are likely blending the concept of altered gene expression profiles—a hallmark of cancer—with the entirely separate concept of genomic instability, committing a category error.

Option D — 'Increased gene pool variation' — misapplies population-genetics vocabulary to a cell-biology problem. 'Gene pool' refers to the aggregate of alleles across a population of sexually reproducing organisms, a concept tied to meiosis, independent assortment, and allelic segregation within Unit 5. A single malignant clone accumulating somatic mutations does not possess a 'gene pool' in the Mendelian sense. This option exploits superficial familiarity with evolutionary language and tests whether the student can distinguish between population-level genetic variation arising from meiotic recombination and the cell-level mutational burden generated by defective DNA repair in a somatic lineage.